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Non-alcoholic fatty liver disease (NAFLD) affects over 20% of people in the West, and up to one third of people living in South America or the Middle East ([@B81]). NAFLD is defined by the presence of hepatic steatosis in the absence of a secondary cause (e.g., excessive alcohol consumption or drugs). It is associated with hypertension and a number of metabolic co-morbidities, including obesity, type 2 diabetes mellitus (T2DM), hyperlipidemia, and metabolic syndrome ([@B79]). NAFLD is a disease spectrum that comprises simple steatosis, non-alcoholic steatohepatitis (NASH), and fibrosis which can lead to cirrhosis and hepatocellular carcinoma (HCC) ([@B11]; [@B75]; [@B2]). The determinants of progression through this spectrum are not completely understood, but increased visceral adiposity, insulin resistance, lipotoxicity, inflammation, environmental factors such as diet as well as genetics are likely to play a role. There are currently no drugs licensed for the treatment of the NAFLD spectrum although many are in development.

A large body of evidence indicates that cardiovascular disease (CVD) is a common cause of death among patients with NAFLD ([@B51]; [@B56]; [@B65]; [@B4]; [@B70]; [@B37]; [@B80]) although this is not a universal finding ([@B31]; [@B77]; [@B83]; [@B1]; [@B39]). Some of this dissonance may relate to variable adjustment for existing risk factors including diabetes, obesity, smoking, ethnicity, and social deprivation. Therefore, while some evidence suggests increased CVD risk, and the two disease states share common pathological mechanisms \[e.g., oxidative stress, inflammation, and endothelial dysfunction ([@B32]; [@B21])\], a causal relationship has yet to be proven.

Nevertheless, there is a drive to discover therapeutic strategies that combine hepatic efficacy with reducing CVD risk in this multi-morbid population who carry many metabolic risk factors. One possible solution may lie in the genetics of these conditions. If NASH and CVD are closely linked, it is plausible to hypothesize that genetic variants that confer adverse risk and that are shared between disease states encode potential therapeutic targets that may meet treatment goals. Over 163 genetic loci are associated with CVD ([@B17]), and a much smaller number of loci with NAFLD spectrum ([@B18]) but there is minimal overlap between these groups of genes. Here, we review the genetic associations with disease states in the NAFLD spectrum and the evidence, if any, of their role in CVD.

Genetics of Non-Alcoholic Fatty Liver Disease {#s1_1}
---------------------------------------------

Genome wide association studies (GWAS) have enabled the association of genetic polymorphisms with disease state or treatment response ([@B18]). Limitations of GWAS include absence of causality, requirement for very large sample sizes and difficulties in interpreting heritability in complex polygenic conditions such as NAFLD ([@B67]). Different endpoints have been used in NAFLD GWAS including histology, imaging-based hepatic fat content, serum liver enzymes, and presence of HCC, contributing to heterogeneity. Here we focus primarily on candidate NAFLD risk genes with consistent results in discovery GWAS or meta-analyses of GWAS, and validated using candidate gene studies, a strategy described in a recent study clustering NAFLD associated genes ([@B8]). We also highlight other genes not identified with GWAS, but have significant associations with CVD in retrospective studies or meta-analyses of retrospective studies, and outline their association with NAFLD ([**Table 1**](#T1){ref-type="table"}).

###### 

Summary of genetic variants and their effects on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

  Genetic variant       Effect                                                                                                        Reference(s)
  --------------------- ------------------------------------------------------------------------------------------------------------- --------------------------
  PNPLA3 I148M          Increases hepatic fat content, and risk of hepatic steatosis, fibrosis, and HCC                               ([@B54]; [@B61]; [@B33])
  TM6SF2 E167K          Increases levels of hepatic triglyceride content, ALT, and increased risk of hepatic fibrosis                 ([@B28]; [@B34])
  MBOAT7 rs614738       Increases hepatic triglyceride content, and risk of hepatic steatosis, fibrosis, and HCC                      ([@B9]; [@B38]; [@B15])
  GCKR rs780094         Increased hepatic steatosis and fibrosis                                                                      ([@B63]; [@B44])
  NCAN P92S             Increased risk of hepatic steatosis, lobular inflammation, and fibrosis                                       ([@B63]; [@B22])
  PPP1R3B rs4240624     Increased risk of hepatic steatosis                                                                           ([@B63])
  PPP1R3B rs6175625     Predictor of ultrasonography diagnosed NAFLD                                                                  ([@B14])
  TRIB1 rs2954021       Associated with raised ALT and increased risk of histological or ultrasonography diagnosed NAFLD              ([@B12]; [@B26]; [@B35])
  ERLIN1-CHUK-CWF19L1   Increased risk of CT-diagnosed NAFLD and raised ALT                                                           ([@B20])
  PEMT V175M            Increased risk of histologically diagnosed NAFLD and NASH, and ultrasonography/MRS diagnosed NAFLD            ([@B68])
  MTTP 493G \> T        Increased risk of biopsy proven NAFLD and NASH, and ultrasonography diagnosed NAFLD                           ([@B85])
  SOD2 rs4880           Increased risk of fibrosis steatohepatitis and fibrosis                                                       ([@B3])
  UCP2 866 G \> A       Reduced risk of NASH, more pronounced effect in those without impaired fasting glucose or diabetes mellitus   ([@B19])

Patatin-Like Phospholipase Domain-Containing Protein 3 (Aliases: Adiponutrin, Calcium-Independent Phospholipase A2-Epsilon, or Acylglycerol O-Acyltransferase) {#s1_2}
--------------------------------------------------------------------------------------------------------------------------------------------------------------

PNPLA3 hydrolyses triglycerides and retinyl esters ([@B23]) and is associated with NAFLD in GWAS ([@B54]). The I148M variant (isoleucine to methionine substitution at amino acid position 148) of *PNPLA3* has reduced hydrolase activity and impairs retinyl ester release, resulting in accumulation of triglycerides and retinyl esters within hepatocytes and stellate cells and increased hepatic fat content ([@B45]; [@B47]; [@B6]). Upregulation of wild-type *PNPLA3* reduces secretion of matrix metalloproteinases and tissue inhibitor of metalloproteinases, protecting against fibrosis ([@B46]).

*PNPLA3* I148M (rs738409 C \> G) is significantly associated with imaging-assessed hepatic fat content, adjusted for body mass index (BMI), diabetes status, ethanol use, and ethnicity (p = 7.0x10^−14^) ([@B54]). This allele significantly increases the risk of hepatic steatosis and fibrosis independent of age, sex, BMI, and homeostatic model of insulin resistance (HOMA) index, in a "dose-dependent" manner, with intermediate severity of steatosis in heterozygotes and more severe steatosis in homozygotes (G/G) ([@B61]; [@B71]). Cross-sectional studies show the G allele is more frequent in histologically confirmed steatosis (frequency: 49.2%, p = 2x10^−3^) and NASH (frequency: 51.8%, p = 4x10^−26^) compared with normal controls (frequency: 22.8%). Risk of bridging fibrosis increases with each G allele (OR 1.50, 95% CI 1.19--1.89), independently of steatosis and inflammation ([@B55]). The rs738409 C \> G polymorphism is also associated with increased HCC risk (OR: 2.046, 95% CI 1.47--2.84, χ^2^ ^=^ 18.50, p \< 0.0001), and additive modeling showed that G/G homozygosity conferred a fivefold increase in risk compared with C/C homozygous NAFLD controls (OR: 5.05, 95% CI 1.47--17.29, p = 0.01) ([@B33]). A meta-analysis of 24 studies with a total of 9,195, mostly Caucasian, patients concluded that PNPLA3 I148M is significantly associated with increased risk of advanced fibrosis in individuals with NAFLD (OR: 1.23, 95% CI 1.10--1.37) and of HCC (OR: 1.67, 95% CI 1.27--2.21) in patients with NAFLD ([@B59]).

In non-Caucasian cohorts, there is also strong evidence for an association of PNPLA3 with NAFLD. In two Japanese cohorts the PNPLA3 rs738409 variant was significantly associated with NAFLD (OR: 1.66, 95% CI 1.43--1.94, p = 1.4x10^−10^), and, in particular, a more severe histological subtype ([@B24]; [@B25]), with similar findings in a large Korean cohort ([@B13]). PNPLA3 I148M is therefore strongly associated with the NAFLD spectrum in both Caucasian and non-Caucasian cohorts.

Transmembrane 6 Superfamily 2 {#s1_3}
-----------------------------

TM6SF2 encodes a protein that localizes to the endoplasmic reticulum (ER)-Golgi apparatus of hepatocytes, and increases secretion of triglyceride-rich lipoproteins; reduced TM6SF2 expression increases hepatic triglyceride content ([@B36]). TM6SF2 E167K variant (rs58542926 C \> T) is associated with increased levels of hepatic triglyceride content measured using ^1^H-MRS (independently of PNPLA3 I148M), raised serum alanine transaminase (ALT), and reduced serum cholesterol and triglycerides, in a multi-ethnic cohort ([@B28]). The association with serum ALT was confirmed in two further cohorts, of 8,585 European Americans and 73,532 individuals from two Copenhagen-based studies ([@B28]). This variant is associated with increased hepatic fibrosis (β: 0.549 ± 0.135, 95% CI 0.285--1.813, p = 5.57x10^−5^), again independently of PNPLA3 I148M ([@B34]). After adjusting for confounding variables, the co-existence of PNPLA3 rs738409 and TM6SF2 rs58542926 in a Korean cohort increased the risk of NASH (OR per risk allele: 2.03, 95% CI 1.50--2.73 p \< 0.001) and significant fibrosis (OR for each risk allele: 1.61, 95% CI 1.19--2.17, p \< 0.002) ([@B27]) with similar findings from a Chinese cohort (OR for each allele 1.52, regression line R^2^ = 0.992) ([@B74]). Thus TM6SF2 E167K is associated with stages of NAFLD independently of PNPLA3 I148M.

Membrane Bound O-Acyltransferase Domain Containing 7 {#s1_4}
----------------------------------------------------

MBOAT7 is highly expressed in hepatocytes, hepatic stellate cells, and hepatic sinusoidal cells, and the rs641738 T allele increases risk of hepatic triglyceride content and NAFLD spectrum, with each T allele increasing the risk of steatosis (OR: 1.42, 95% CI 1.07--1.91, p = 0.015), NASH (OR: 1.18, 95% CI 1.00--1.40, p = 0.05), hepatic fibrosis stage F2-4 (OR: 1.30, 95% CI 1.06--1.70, p = 0.012), and HCC in the absence of advanced fibrosis (OR: 2.10, 95% CI 1.33--3.31) ([@B9]; [@B38]; [@B15]). *MBOAT7, PNPLA3*, and *TM6SF2* risk loci confer a stepwise risk of increased hepatic fat content per each additional risk allele ([@B38]).

Glucokinase Regulatory Protein {#s1_5}
------------------------------

The GCKR rs780094 polymorphism is significantly associated with CT- and histologically proven hepatic steatosis in GWAS (OR = 1.45, p = 2.59x10^−8^) ([@B63]) and in meta-analysis of five studies (2,091 NAFLD cases and 3,003 controls) (OR: 1.25, 95% CI 1.14--1.36, p \< 0.00001, I^2^ = 0%) ([@B82]). This polymorphism is associated with higher expression of GCKR ([@B53]), and with reduced risk of T2DM ([@B62]; [@B41]). In patients with NAFLD the rs780094 C \> T polymorphism is significantly associated with hepatic fibrosis stage \> F1 (OR: 2.06, 95% CI 1.02--1.14, p = 0.0008) ([@B44]). The rs1260326 P446L variant is not inhibited by fructose-6-phosphate, resulting in increased activity of glucokinase, hepatic uptake of glucose ([@B7]), and *de novo* lipogenesis ([@B5]). In individuals who carried GCKR rs1260326, *PNPLA3* rs738409, *TM6SF2* rs58542926, and *MBOAT7* rs641738 variants (n = 218 NAFLD/445 total) there was a fivefold increased risk of steatosis (OR: 4.97, 95% CI 2.51--9.83) ([@B14]).

Neurocan Core Protein {#s1_6}
---------------------

The Speliotes GWAS identified a number of other loci associated with NAFLD. NCAN rs2228603 T variant (P92S) is associated with increased risk of histological steatosis (1.22, SE 0.07 in presence of T allele *vs.* 1.03, SE 0.03 for CC genotype, p = 0.03), lobular inflammation (39.7% in presence of T allele *vs.* 30.1% for CC genotype, p = 0.02), and presence of fibrosis (27.8% in presence of T allele *vs.* 17.2% for CC genotype, p = 0.002) in patients undergoing bariatric surgery ([@B22]). NCAN is a proteoglycan involved in remodeling central nervous system extracellular matrix ([@B52]), also expressed in the liver ([@B40]).

Protein Phosphatase 1 Regulatory Subunit 3B {#s1_7}
-------------------------------------------

PPP1R3B rs4240624 is associated with CT-diagnosed hepatic steatosis, but not histological evidence of inflammation and fibrosis ([@B63]) and the *PPP1R3B* rs61756425 variant is a strong predictor of severe NAFLD on ultrasound (OR: 32.6, 95% CI 4.22--251.4, p = 0.001) ([@B14]). The mutated PPP1R3B results in excess hepatic glycogen (but not triglyceride), resulting in hepatic injury ([@B64]).

Tribbles Pseudokinase 1 {#s1_8}
-----------------------

TRIB1 rs2954021 G \> A allele is significantly associated with raised ALT ([@B12]) and histologically or ultrasound-diagnosed NAFLD (OR: 1.52, 95% CI 1.23--1.88, p = 9.7x10^−5^) (OR: 2.050, 95% CI 1.110--3.786, p = 0.022) ([@B26]; [@B35]).

Genetic Associations Not Discovered Through Genome Wide Association Studies {#s1_9}
---------------------------------------------------------------------------

A correlated meta-analysis identified nine *ERLIN1-CHUK-CWF19L1* gene variants associated with CT-diagnosed NAFLD and raised ALT levels ([@B20]). *Phosphatidylethanolamine N-methyltransferase (PEMT)* loss of function results in impaired lipid removal from the liver due to reduced levels of hepatic phosphatidylcholine, which mediates triglyceride secretion from hepatocytes ([@B60]; [@B72]). Although not demonstrated in GWAS, a meta-analysis of 6 studies showed that the PEMT rs7046 A allele (V175M) is associated with NAFLD in East-Asian populations (OR 1.55, 95% CI 1.13--2.11, p = 0.005) ([@B68]). *Mitochondrial transport protein (MTTP)* 493 G \> T polymorphism is associated with NAFLD (G *vs.* T allele OR: 1.46, 95% CI 1.20--1.78, p \< 0.001), albeit in meta-analysis, not GWAS ([@B85]). *Superoxide dismutase 2 (SOD2)* is involved in removal of reactive oxygen species in mitochondria ([@B76]). In a case-control study of 502 patients with biopsy-proven NAFLD, SOD2 rs4880 was associated with a dose-related increased risk of advanced fibrosis (p = 0.008 for trend) but not steatohepatitis ([@B3]). *Uncoupling protein 2 (UCP2)* has a role in regulating lipid efflux and oxidative metabolism, and homozygous 866 G \> A is associated with increased hepatic protein levels and reduced risk of NASH (adjusted OR: 0.49, 95% CI: 0.26--0.90, p = 0.02) ([@B19]).

Are There Common Genetic Associations Shared Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease? {#s1_10}
------------------------------------------------------------------------------------------------------------------

Cardiovascular disease is a broad term comprising coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease that are largely driven by atherosclerosis ([@B66]). While events such as fatal or non-fatal myocardial infarction or stroke may be clinically more meaningful, surrogate markers of CVD including carotid intima-media thickness, carotid artery plaques, and CT-based coronary artery calcification have been used as study endpoints ([@B42]). The genetics of CVD that have identified over 160 loci associated with CAD at a genome-wide level of significance have been reviewed elsewhere ([@B17]).

*PNPLA3* I148M allele had a small, statistically significant (albeit not to GWAS levels of significance) protective effect (OR: 0.92, 95% CI 0.87--0.97, p = 0.002) against CVD, in a meta-analysis of 48 GWAS including 60,801 cases with CVD ([@B58]). This may relate to reduced levels of circulating triglycerides ([@B69]). A recent prospective study of patients undergoing elective coronary angiography found that while there was a non-significant trend for a protective effect of the presence of PNPLA3 I148M and CAD \>75% stenosis, when corrected for age, sex, use of statins, and serum high-density lipoprotein, there was a significant protective effect (OR: 0.21, 95% CI 0.05--0.88, p = 0.03) ([@B50]). Mendelian randomization has been used to assess the association of *PNPLA3* I148M with ischemic heart disease (IHD), and although the risk of IHD increases with increased hepatic fat content, for which *PNPLA3* I148M is a risk factor, there was no association with IHD (OR per M allele = 0.98, 95% CI 0.95--1.02, p = 0.79) ([@B30]).

Interestingly, presence of PNPLA3 I148M variant has been shown to confer a small, but significant risk of premature CAD (defined as MI, angioplasty, revascularization surgery, coronary stenosis \>50% diagnoses before the age of 55 in men, and 65 in women) only in those with T2DM (OR 1.20, 95% CI 1.01--1.42, p = 0.042), in a study of 1,103 individuals with premature CAD and 1,469 healthy controls ([@B49]). Homozygous PNPLA3 I148M genotype confers greater risk of more severe carotid artery intima-media thickness (IMT) in 162 patients with biopsy-proven NAFLD aged \< 50 (OR 2.94, 95% CI 1.12--7.70, p = 0.02), validated in 267 patients with clinical or histological NAFLD ([@B43]).

The *TM6SF2 E167K* variant which is associated with hepatic steatosis, fibrosis, and HCC development was protective against CVD with lower total cholesterol, LDL-cholesterol, and serum triglycerides in a meta-analysis of 10 studies ([@B48]). A further meta-analysis of 48 GWAS including 60,801 cases with CVD confirmed a small reduction in CVD risk with *TM6SF2* E167K (OR: 0.95, 95% CI 0.92--0.98, p = 0.005) ([@B58]), and in a smaller cross-sectional study, it was associated with reduced risk of carotid artery plaques (OR: 0.49, 95% CI 0.25--0.94) ([@B16]). As described, this variant is associated with raised serum ALT levels, however a recent Mendelian randomization study has also suggested that raised ALT levels may reduce the risk of IHD, and this may be due to a reduction in serum triglyceride levels ([@B78]).

*PEMT* rs12936587 variant was associated with increased susceptibility to CAD (OR 1.07, 95% CI 1.05--1.09, p = 4.45x10^−10^) ([@B57]) in a meta-analysis of 14 GWAS (22,233 cases of CAD and 64,762 controls). However, there was no association with cardiovascular events (IHD, CVA, peripheral arterial disease), and atherosclerosis determined by carotid intima-media wall thickness (IMT) by carotid ultrasonography in a detailed study of 2,609 Spanish individuals ([@B29]).

*TRIB1* rs2954021 variant is associated with increased risk of IHD (15% increased risk in AA *vs.* TT genotype, 95% CI 5--20%) and MI (17% increased risk in AA *vs.* TT genotype, 95% CI 6--30%) ([@B73]) ([@B10]). TRIB1 rs2954021 and rs231150 are associated with increased risk of coronary heart disease (rs2954021 OR for A *vs.* T allele in log-additive model: 1.36, 95% CI 1.14--1.63, p \< 0.001, rs231150 OR for A *vs.* T allele in log-additive model: 1.36, 95% CI 1.14--1.63, p \< 0.0015), and TRIB 1 rs2954021 is also associated with increased risk of ischemic stroke across genetic models (OR for A *vs.* T allele in log-additive model: 1.30, 95% CI 1.09--1.55, p = 0.0039) ([@B84]). However, in this study controls were not matched for key risk factors and patients with CAD and stroke had higher BMI, systolic blood pressure, pulse pressure, and triglyceride levels and lower prevalence of alcohol consumption, and ratio of ApoA1:ApoB.

The clustering of 12 genetic variants associated with NAFLD by weighted fixed-effects statistical modeling showed no association with CAD or MI (OR: 1.00, 95% CI 0.99--1.01, p = 0.93) ([@B8]). Restricting this analysis to the four most validated genes (*PNPLA3*, *TM6SF2*, *GCKR*, and *MBOAT7*) also resulted in a null association (OR: 0.99, 95% CI 0.98--1.00) ([@B8]).

Discussion and Implications on Treatment of Non-Alcoholic Fatty Liver Disease {#s1_11}
-----------------------------------------------------------------------------

GWAS have identified genes that are associated with NAFLD, many of which have been further validated in observational data. Though GWAS do have certain limitations as described, there are at least 4 genes that have been extensively validated in their association with NAFLD. However, the genes most robustly associated with NAFLD do not appear to contribute to increased cardiovascular risk in terms of CAD, and in fact *TM6SF2* E167K is protective against CVD (IHD and ischemic stroke), and *PNPLA3* I148M exerts no significant effect on CVD. Where associations have been described in *TRIB1* and *PEMT* (albeit different SNPs), the studies have shown null associations with 'hard' clinical endpoints or suffered incomplete matching of controls. This does not mean that there is no independent association of fatty liver with CVD; rather the complex relationship probably requires much larger studies powered to detect the association as well as Mendelian randomization and interaction studies.

Given that no drugs are licensed to treat the NAFLD spectrum, management focuses on lifestyle modification. Ideally, therapy would treat liver disease, and also improve clinical endpoints including mortality. Therefore improved patient outcomes may be achieved by interventions that improve control of T2DM, lipids, blood pressure, and obesity rather than have profound effects in the liver. While there is evidence to support a degree of genetic risk in each disease spectrum individually, there is little to no evidence of any shared genetic risk. Therefore while knowledge of genetic loci is potentially useful for risk stratification of patients with NAFLD, therapeutic targeting of the products of these genes as a strategy that improves both liver and cardiovascular health has yet to be proven.
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